Burning Rock Biotech Ltd BNR
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2020-06-12
Burning Rock Biotech Ltd financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $77.2M | $70.7M | $75.7M | $81.7M | $79.7M | $65.9M | $381.7M |
| Gross profit | $57.6M | $49.6M | $51.2M | $55.1M | $57.1M | $48.1M | $273.3M |
| R&D expense | $23.8M | $31.8M | $48.9M | $61.2M | $57.7M | $40.5M | $156.9M |
| Operating income | -$7.8M | -$49.0M | -$94.3M | -$142.1M | -$125.1M | -$63.2M | -$169.1M |
| Interest expense | — | — | — | — | $241,000 | $102,000 | $9.0M |
| Income tax | $223,000 | $806,000 | $336,000 | $288,000 | $141,000 | $0 | $0 |
| Net income | -$7.9M | -$47.5M | -$92.1M | -$140.8M | -$125.0M | -$62.4M | -$169.2M |
| Operating cash flow | -$4.1M | -$12.6M | -$36.0M | -$66.2M | -$75.0M | -$11.3M | -$228.0M |
| Free cash flow | -$4.8M | -$13.4M | -$37.2M | -$75.2M | -$107.1M | -$20.5M | -$271.0M |
| Cash & equivalents | $68.4M | $71.2M | $86.6M | $131.3M | $224.6M | $290.5M | $94.2M |
| Inventory | $6.9M | $8.6M | $9.7M | $18.9M | $19.3M | $10.4M | $58.1M |
| Total assets | $117.3M | $121.3M | $146.5M | $230.2M | $357.6M | $408.1M | $847.6M |
| Total liabilities | $40.8M | $41.7M | $38.3M | $62.2M | $68.0M | $37.1M | $212.0M |
| Shareholders' equity | $76.5M | $79.6M | $108.2M | $167.9M | $289.6M | $371.0M | -$891.5M |
Growth · year-over-year · Revenue CAGR -23.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +9.2% | -6.6% | -7.3% | +2.5% | +21.0% | -82.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.